Hainan Shuangcheng Passes U.S. FDA Inspection

2019-07-01 16:54
Hainan Shuangcheng Pharmaceuticals Co., Ltd (the “company”) has received the unannounced on-site inspection by the U.S. FDA from 16 April to 24 April 2019, regarding the API, API intermediates and finished dosage form.
Recently, the company has received the acceptance letter from the U.S. FDA that the facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).

上一篇:Pregabalin Capsule ANDA Approved by U.S. FDA
下一篇:Eptifibatide DMF Passes U.S. FDA Review